Mihailo I. Stjepanovic

Belgrade, SE, Serbia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Discharge Practices After Hospitalization for COPD Exacerbations: A Physician Survey and SWOT Analysis.

Discharge Practices After Hospitalization for COPD Exacerbations: A Physician Survey and SWOT Analysis.

Journal: Healthcare (Basel, Switzerland)

Published: May 10, 2026

Early Functional Impairment in Smokers with CT-Detected Emphysema: Spirometry Provides Complementary Physiological Information in Lung Cancer Screening.

Early Functional Impairment in Smokers with CT-Detected Emphysema: Spirometry Provides Complementary Physiological Information in Lung Cancer Screening.

Journal: Biomedicines

Published: February 22, 2026

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Journal: Cancers

Published: January 13, 2026

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.

Journal: Medicina (Kaunas, Lithuania)

Published: December 12, 2025

PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma.

PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma.

Journal: Cells

Published: December 12, 2025

Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Journal: Current oncology (Toronto, Ont.)

Published: December 10, 2025

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

Journal: The Lancet. Respiratory medicine

Published: August 03, 2025

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience.

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience.

Journal: Cancers

Published: August 02, 2025

Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy.

Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy.

Journal: Genes

Published: July 15, 2025

Clinical Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis: Analysis of the Serbian Cohort from the EMPIRE Registry.

Clinical Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis: Analysis of the Serbian Cohort from the EMPIRE Registry.

Journal: Diagnostics (Basel, Switzerland)

Published: June 27, 2025

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: May 20, 2025

The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

Journal: Cancers

Published: April 27, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026